Pharmaceutical Executive-05-01-2019

Pharmaceutical Executive

Impact Investing and R&D

May 13, 2019

Features

39

5

Private equity investment and venture capital have long spurred R&D efforts for hard-to-treat conditions. Joining the mix of late has been impact investing and the opportunities for the socially-conscious to influence drug development-and reap potential benefits in health outcomes and financial return.

Dollars and Digital: The Future of Pharma Finance

May 09, 2019

Features

39

5

In this executive roundtable, pharma and biotech finance leaders discuss the pace of digital technology adoption in accounting and reporting, and the growing recognition of data and analytics-over traditional numbers crunching-in delivering deeper business insights across the organization.

New Flare-Up in Europe's External Reference Pricing Debate

May 08, 2019

Columns

39

5

European industry fights over every inch on comparative drug pricing initiative.

Survey Spotlights the CFO’s Strategic Rise

May 07, 2019

Features

39

5

Findings support the belief that today’s pharma finance teams should be engaged across all functional areas, including regulatory, supply chain, manufacturing, and commercial. What does that mean for current and future CFOs in the industry?

Pharmaceutical Executive, May 2019 Issue (PDF)

May 01, 2019

Issue PDF

39

5

Click the title above to open the Pharmaceutical Executive May 2019 issue in an interactive PDF format.

Country Report: Korea

May 01, 2019

Special Sponsored Section

39

5

Following its economic rise in recent decades, driven by innovation across a wide variety of powerhouse industries, South Korea is setting its sights on the next generation of technological growth-including new strategies to globalize and industrialize the nation’s pharmaceutical and healthcare sector.